FPFeng Peng

Feng Peng

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Feng Peng has a total of 94 co-authors. Here are the top co-authors by number of shared publications:

  • Jinxiu Lin

    Department of Cardiology, The First Affiliated Hospital, Fujian Medical University, Fuzhou, China

    8 shared publications
  • Jinxiu Lin

    Fujian Hypertension Research Institute, The First Affiliated Hospital of Fujian Medical University, Fuzhou, People’s Republic of China

    6 shared publications
  • Laicheng Wang

    Department of Cardiology, Fujian Medical University Union Hospital, Fuzhou, China

    6 shared publications
  • Yunchai Lin

    Department of Cardiology, the First Affiliated Hospital of Fujian Medical University, Fuzhou, China

    6 shared publications
  • Changsheng Xu

    Fujian Provincial Institute of Hypertension, The First Affiliated Hospital, Fujian Medical University, Fuzhou 350005, China

    5 shared publications
  • Dajun Chai

    Cardiovascular Department, The First Affiliated Hospital, Fujian Medical University, Key Laboratory of Metabolic Heart Disease in Fujian Province, Clinical Research Centre of Metabolic Cardiovascular Disease in Fujian Province

    5 shared publications

Latest Publications

  • ACE2 ameliorates DOX-induced cardiotoxicity by suppressing excessive autophagy via the AMPK/mTOR signaling pathway

    by Jingjing Gong, Qingqing Li, Mei Lin, Changsheng Xu, Dajun Chai, Jinxiu Lin, Feng Peng

  • Open Access

    MIR-128 TARGETING PPAR-γ IMPROVES VASCULAR REMODELING IN SPONTANEOUSLY HYPERTENSIVE RATS BY REGULATING THE TLR4/NFKB INFLAMMATORY PATHWAY

    by Zhoufei Fang, Han Cai, Ruonan Liu, Lele Yu, Chunxian Chen, Shikun Chen, Lirong Li, Qiujing Chen, Huange Cai, Jinzi Su, et al.

    OBJECTIVE: This study aimed to explore the role and underlying mechanism of microRNA-128 (miR-128) in regulating vascular remodeling in spontaneously hypertensive rats (SHRs), focusing on its targeting of peroxisome proliferator-activated receptor γ (PPAR-γ) and modulation of the Toll-like receptor 4/nuclear factor-κB (TLR4/NF-κB) inflammatory pathway. METHODS: All experimental procedures were approved by the Animal Care and Use Committee of Fujian Medical University. In vivo, ten-week-old male SHRs were randomly assigned to three groups: renal denervation (RDN, n=6), sacubitril/valsartan (Sac/Val, n=6), and Sham (n=6). Age-matched Wistar-Kyoto (WKY) rats served as normotensive controls (n=6).Eight weeks after intervention, mesenteric arteries were harvested for histological, functional, and molecular analyses. Serum miR-128 levels were measured by quantitative real-time polymerase chain reaction (qRT-PCR). The expression levels of key proteins in the vascular wall were assessed via immunofluorescence (IF), immunohistochemistry (IHC), and Western blotting (WB). Bioinformatics analysis and RNA sequencing (RNA-seq) were employed to identify core genes and signaling pathways associated with hypertension-induced pathological inflammation. RESULTS: In vivo, in the SHR sham-operated group, elevated blood pressure, severe vascular remodeling, and impaired vasodilatory function were observed, accompanied by downregulated miR-128 expression and upregulated TLR4/NF-κB signaling activity (all p < 0.0001).RDN postoperative, miR-128 expression was significantly restored, which in turn inhibited the TLR4/NF-κB pathway, reduced the production of pro-inflammatory cytokines (including IL-1β, IL-6, and TNF-α), and ameliorated vascular dilation dysfunction in SHRs (all p < 0.0001). Mechanistically, miR-128 negatively regulated the TLR4/NF-κB signaling pathway while upregulating the expression of PPAR-γ (p < 0.05). CONCLUSION: RDN not only exerts a hypotensive effect but also improves hypertensive vascular remodeling. miR-128 inhibits excessive inflammation in vascular smooth muscle cells and alleviates vascular remodeling in SHRs via the PPAR-γ/TLR4/NF-κB axis. These findings identify miR-128 as a potential therapeutic target for RDN in the treatment of hypertension, providing a novel regulatory strategy for the precision management of cardiovascular diseases.

  • Open Access

    Osteoporosis therapies and coronary risk: insights from vascular calcification biology and sclerostin signaling

    by Shuwei Weng, Chen Ding, Yuhong Shi, Hailin Zhang, Wenxiang Zhao, Jiang Zhu, Feng Peng, Dajun Chai

    Osteoporosis therapies have become increasingly relevant to cardiovascular medicine because the bone–vascular interface links skeletal remodeling to vascular calcification biology. This narrative review examines whether anti-osteoporosis therapies truly modify coronary biology or risk, or whether the current literature more often reflects heterogeneous vascular end points, indirect coronary inference, and incomplete translation from mechanistic plausibility to clinical outcomes. We summarize the biologic pathways connecting bone remodeling to vascular calcification, including osteogenic transdifferentiation of vascular smooth muscle cells, matrix vesicle-mediated mineralization, the OPG/RANKL axis, and Wnt–sclerostin signaling. We then reassess current evidence for antiresorptive and osteoanabolic therapies while distinguishing coronary-specific data from broader vascular, renal-mineral, pharmacovigilance, and genetic evidence. Bisphosphonates and denosumab remain biologically relevant to vascular calcification, but based on currently available evidence, current studies do not support a reproducible or clinically decisive effect on coronary-specific outcomes. By contrast, romosozumab has sharpened the debate because it combines robust anti-fracture efficacy with unresolved cardiovascular safety questions linked to sclerostin inhibition, whose mechanistic, genetic, and clinical signals are not fully concordant. We further discuss why the literature remains conflicted, emphasizing end point heterogeneity, differences between calcification burden and plaque vulnerability, population-specific mineral stress, and the limitations of fracture trials for coronary inference. Overall, current evidence does not support a uniform cardiovascular class effect of osteoporosis therapies; instead, vascular consequences appear drug-specific, context-dependent, and highly sensitive to phenotype, baseline risk, and time horizon.

  • Open Access

    Association of C-reactive protein to albumin ratio with prevalence and mortality in metabolic syndrome: NHANES 1999–2010

    by Laicheng Wang, Chennan Liu, Xuan Zheng, Ailing Wang, Yunchai Lin, Feng Peng

    Metabolic syndrome (MetS) is closely related to inflammation and oxidative stress. C-reactive protein to albumin ratio (CAR) is an inflammatory and nutriti


  • Open Access

    Single-cell and bulk transcriptome analyses revealed the role of macrophage cholesterol metabolism in atherosclerosis

    by Jiaxing Ke, Shuling Chen, Lingjia Li, Chenxin Liao, Feng Peng, Dajun Chai, Jinxiu Lin

    Atherosclerosis (AS) is a complex cardiovascular disease characterized by dysregulated macrophage cholesterol metabolism (CM), a central driver of foam cel


  • Open Access

    NEDD4L-Mediated Ubiquitination of GPX4 Exacerbates Doxorubicin-Induced Cardiotoxicity

    by Jiaxing Ke, Lingjia Li, Shuling Chen, Chenxin Liao, Feng Peng, Dajun Chai, Jinxiu Lin

    Doxorubicin (DOX) is an anthracycline chemotherapeutic agent that is clinically limited by doxorubicin-induced cardiotoxicity (DIC), with ferroptosis and apoptosis identified as key mechanisms. As an antioxidant enzyme, GPX4 undergoes ubiquitin-mediated degradation during myocardial ischemia–reperfusion injury; however, the role of its ubiquitination in DIC remains unclear. This study revealed that GPX4 undergoes ubiquitinated degradation during DIC, exacerbating ferroptosis and apoptosis in cardiomyocytes. NEDD4L was found to interact with GPX4, and its expression was upregulated in DOX-treated mouse myocardial tissues and cardiomyocytes. NEDD4L knockdown alleviated DIC, as well as ferroptosis and apoptosis in cardiomyocytes. Mechanistically, NEDD4L recognizes GPX4 through its WW domain and mediates K48-linked ubiquitination and degradation of GPX4 under DOX stimulation via its HECT domain. Knockdown of NEDD4L reduced DOX-induced GPX4 ubiquitination levels and subsequent degradation. Notably, while NEDD4L knockdown mitigated DOX-induced cell death, concurrent GPX4 knockdown attenuated this protective effect, indicating that GPX4 is a key downstream target of NEDD4L in regulating cardiomyocyte death. These findings identify NEDD4L as a potential therapeutic target for preventing and treating DIC.


  • Open Access

    The utility of 68Ga-pentixafor PET/CT in superselective adrenal artery embolization(SAAE) for treating aldosterone adenomas

    by Fang Zhoufei, Zhang Qixiang, Zhou Wei, Lin Jinxiu, Peng Feng, Cai Han

    Purpose: Expression of CXC chemokine receptor 4 (CXCR4) has proved to be a valuable tool for guiding the diagnosis and treatment of aldosterone-producing adenoma (APA). In this study, we evaluated whether CXCR4 imaging with 68 Ga-pentixafor PET/CT shows significant changes after superselective adrenal artery embolization (SAAE). Methods: We prospectively recruited 25 patients with clinically diagnosed APA. All patients were examined with 68 Ga-pentixafor PET/CT and adrenal venous blood sampling (AVS) before and after SAAE. PET/CT showed that the tracer uptake of unilateral nodular adrenal gland was higher than that of normal adrenal tissue. AVS showed that the dominant secretory side was consistent with that on PET/CT. All patients were successfully treated with SAAE. Clinical follow-up was carried out according to primary aldosteronism surgical outcome (PASO) criteria, and included monitoring of drug type, blood pressure, serum potassium, and aldosterone/renin ratio to evaluate surgical effect. Post operation 68 Ga-pentixafor PET/CT and the maximum standardized uptake value (SUVmax) were used to observe the uptake of adrenal lesions after SAAE. Results: Among the 25 APA patients who successfully underwent SAAE, 14 were men and the average age was 51.88 ± 8.89 years. The consistency between AVS and 68 Ga-pentixafor PET/CT reaches 100%. Before operation, the SUVmax of the diseased side (16.79 ± 2.51, n = 25) was significantly higher than that of the non-diseased side (4.56 ± 0.57, P < 0.01). According to PASO criteria, 13 of 25 patients achieved complete clinical remission, 9 achieved partial remission and the treatment was ineffective for three patients. 19 cases achieved biochemical complete remission and 3 cases achieved partial remission. Following the treatment, 22 patients showed complete or partial remission. The 68 Ga-pentixafor SUVmax of the diseased side decreased significantly (16.75 ± 2.54 vs. 4.37 ± 1.52, n = 22, P < 0.001). For the patients who ineffective to the treatment, the SUVmax did not change (17.07 ± 2.72 vs. 16.17 ± 2.72, n = 3, P = 0.842). The 25 patients were divided into two groups according to the average value (≥ 65% and < 65%) of the decrease in SUVmax. The decrease in SUVmax correlated with a good patient prognosis under the PASO standard ( P = 0.009). Conclusion: A decrease in SUVmax is related to the prognosis. CXCR4 imaging with 68 Ga-pentixafor can be used for pre- and post-SAAE evaluation in patients with APA.


  • Open Access

    Genetically predicted ankylosing spondylitis increases the risk of heart failure: a Mendelian randomization study

    by Chennan Liu, Laicheng Wang, Mei Lin, Jing You, Xuan Zheng, Ailing Wang, Yunchai Lin, Feng Peng, Dan Hu

    Background: Observational studies have indicated a potential association between ankylosing spondylitis and elevated cardiovascular disease (CVD) risk. However, it remains uncertain whether this association reflects a causal association. Therefore, we conducted this Mendelian randomization to investigate the causal relationship between ankylosing spondylitis and CVD.Methods: We performed a two-sample Mendelian randomization analysis to establish a causal relationship between ankylosing spondylitis and the risk of six prevalent CVDs: hypertension, heart failure, atrial fibrillation, coronary heart disease, myocardial infarction, and peripheral artery disease. Furthermore, multivariate Mendelian randomization was employed to determine the influence of confounding factors.Results: Genetically predicted ankylosing spondylitis increased the risk of heart failure according to the Mendelian randomization analysis (OR = 1.02; 95% CI = 1.00–1.04; p = 0.030). Multivariate analysis results indicated that the causal relationship between ankylosing spondylitis and heart failure risk remained significant after adjusting for hypertension, diabetes, smoking, body mass index, and pulse wave reflection index. The associations diminished and lost significance after adjusting for pulse wave peak-to-peak time and pulse wave arterial stiffness index.Conclusion: Genetically predicted ankylosing spondylitis increased the risk of heart failure, and the causality may partly be mediated by increased arterial stiffness.


  • Open Access

    Association of serum vitamin D levels with mortality in adults with H-type hypertension: Results from the NHANES database with traditional and machine learning approaches

    by Shuling Chen, Jiaxing Ke, Lingjia Li, Chenxin Liao, Feng Peng, Dajun Chai, Jinxiu Lin

    Objective: This study aimed to investigate the relationship between serum vitamin D (Vit D) levels and the risk of mortality among adults with H-type hypertension, a subtype of hypertension characterized by elevated homocysteine (Hcy) levels. Methods: This retrospective analysis utilized NHANES 2001 to 2006 to examine associations of Vit D and Hcy with mortality in hypertensive adults overall (n=5459), followed by targeted analyses in H-type hypertension (n=2276). The primary endpoints of the study were all-cause mortality and cardiovascular disease mortality, with follow-up through 2019. Weighted multivariable Cox models, mediation analyses, restricted cubic splines, and machine-learning validation were conducted. Results: In the overall hypertensive cohort, H-type hypertension had lower Vit D and higher mortality than non-H-type. Higher Vit D was inversely associated with mortality. Joint risk analysis showed greater risk reduction with Vit D>50 nmol/L and Hcy<10 μmol/L than with either factor alone. Hcy was a mediating factor in the relationship between Vit D and mortality. In H-type hypertension, Vit D showed a linear inverse association with mortality. Vit D was identified as an important variable through LASSO regression for feature selection. Five machine learning models were constructed, and three of them performed well in predicting mortality. Among Vit D-deficient individuals with H-type hypertension, engagement in moderate to vigorous activity was associated with a reduced risk of mortality. Conclusion: Higher serum Vit D levels linked to lower mortality risk in hypertension patients, including H-type hypertension, with significantly higher risk in severe deficiency (<25 nmol/L).